Seven Eight Capital, LP Cytokinetics Inc Transaction History

Seven Eight Capital, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$63.75 - $108.06 $3.52 Million - $5.98 Million	-55,294 Reduced 88.86%	6,935 $486,000
Q4 2023 Feb 13, 2024	BUY	$26.88 - $83.49 $1.67 Million - $5.2 Million	62,229 New	62,229 $5.2 Million
Q1 2023 May 12, 2023	BUY	$33.36 - $45.71 $315,018 - $431,639	9,443 New	9,443 $332,000
Q3 2022 Nov 10, 2022	SELL	$38.54 - $54.52 $497,936 - $704,398	-12,920 Reduced 62.03%	7,907 $383,000
Q2 2022 Aug 04, 2022	BUY	$33.93 - $48.92 $706,660 - $1.02 Million	20,827 New	20,827 $818,000
Q1 2022 May 11, 2022	SELL	$29.74 - $46.0 $267,035 - $413,034	-8,979 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$34.35 - $46.38 $43,933 - $59,320	1,279 Added 16.61%	8,979 $409,000
Q3 2021 Nov 15, 2021	BUY	$18.54 - $35.74 $142,758 - $275,198	7,700 New	7,700 $275,000
Q4 2020 Feb 09, 2021	SELL	$15.26 - $28.61 $439,488 - $823,968	-28,800 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$20.58 - $28.96 $592,704 - $834,048	28,800 New	28,800 $624,000

410

125M

4.6M

2.43M

Ticker CYTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,144,096
Market Cap $4.92B
Description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.